Human Cytomegalovirus Infection and Cardiovascular Disease: Current Perspectives

被引:9
|
作者
Lee, Silvia [1 ,2 ,3 ,4 ,6 ]
Affandi, Jacquita [5 ]
Waters, Shelley [3 ,4 ]
Price, Patricia [3 ,4 ]
机构
[1] Pathwest Lab Med, Dept Microbiol, Perth, WA, Australia
[2] Harry Perkins Inst Med Res, Dept Adv Clin & Translat Cardiovasc Imaging, Murdoch, WA, Australia
[3] Curtin Univ, Curtin Med Sch, Bentley, WA, Australia
[4] Curtin Univ, Curtin Hlth Innovat Res Inst CHIRI, Bentley, WA, Australia
[5] Curtin Univ, Curtin Sch Populat Hlth, Bentley, WA, Australia
[6] Curtin Univ, Curtin Hlth Innovat Res Inst CHIRI, Curtin Med Sch, 208 Kent St, Bentley, WA 6102, Australia
关键词
human cytomegalovirus; cardiovascular disease; atherosclerosis; antibody; T cells; T-CELLS; HIV PATIENTS; TRANSPLANT RECIPIENTS; ENDOTHELIAL-CELLS; ATHEROSCLEROSIS; BURDEN; CMV; PROMOTES; RISK;
D O I
10.1089/vim.2022.0139
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infections with human cytomegalovirus (HCMV) are often asymptomatic in healthy adults but can be severe in people with a compromised immune system. While several studies have demonstrated associations between cardiovascular disease in older adults and HCMV seropositivity, the underlying mechanisms are unclear. We review evidence published within the last 5 years establishing how HCMV can contribute directly and indirectly to the development and progression of atherosclerotic plaques. We also discuss associations between HCMV infection and cardiovascular outcomes in populations with a high or very high burden of HCMV, including patients with renal or autoimmune disease, transplant recipients, and people living with HIV.
引用
收藏
页码:13 / 24
页数:12
相关论文
共 50 条
  • [21] Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives
    M. F. Wu
    K. Z. Xu
    Y. G. Guo
    J. Yu
    Y. Wu
    L. M. Lin
    Cardiovascular Drugs and Therapy, 2019, 33 : 739 - 748
  • [22] Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives
    Wu, M. F.
    Xu, K. Z.
    Guo, Y. G.
    Yu, J.
    Wu, Y.
    Lin, L. M.
    CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (06) : 739 - 748
  • [23] Current Perspectives on Inflammation in Cardiovascular Disease; from Biomarker to Therapy
    de Jager, Saskia C. A.
    Sluijter, Joost P. G.
    JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2021, 14 (01) : 1 - 2
  • [25] Current Perspectives on Inflammation in Cardiovascular Disease; from Biomarker to Therapy
    Saskia C. A. de Jager
    Joost P. G. Sluijter
    Journal of Cardiovascular Translational Research, 2021, 14 : 1 - 2
  • [26] The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives
    Vavuranakis, Michael A.
    Jones, Steven R.
    Cardoso, Rhanderson
    Gerstenblith, Gary
    Leucker, Thorsten M.
    HELLENIC JOURNAL OF CARDIOLOGY, 2020, 61 (06) : 398 - 403
  • [27] Nanotechnology applications for cardiovascular disease treatment: Current and future perspectives
    Wang, Dennis K.
    Rahimi, Maham
    Filgueira, Carly S.
    NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2021, 34
  • [28] Vitamin D and Cardiovascular Disease: Current Evidence and Future Perspectives
    Cosentino, Nicola
    Campodonico, Jeness
    Milazzo, Valentina
    De Metrio, Monica
    Brambilla, Marta
    Camera, Marina
    Marenzi, Giancarlo
    NUTRIENTS, 2021, 13 (10)
  • [29] Human Breast Milk-Acquired Cytomegalovirus Infection: Certainties, Doubts and Perspectives
    Bardanzellu, Flaminia
    Fanos, Vassilios
    Reali, Alessandra
    CURRENT PEDIATRIC REVIEWS, 2019, 15 (01) : 30 - 41
  • [30] Broadsheet number 50: Diagnosis of human cytomegalovirus infection and disease
    Rawlinson, WD
    PATHOLOGY, 1999, 31 (02) : 109 - 115